EFZO-FIT, a Phase 3 trial that’s testing treatment candidate efzofitimod in people with pulmonary sarcoidosis, is continuing following a pre-planned interim safety review, with enrollment expected to finish in the first half of 2024. A data safety and monitoring board (DSMB) examined the trial’s available safety and tolerability…
The prognosis for people with cardiac sarcoidosis may depend on the condition of their heart at diagnosis and not on whether other organs are also affected, a study in Japan suggests. Isolated cardiac sarcoidosis, where the disease is limited to the heart, is a significant risk factor for worse…
For a young man in Belgium, a month-long headache combined with slurred speech and walking difficulties were the result of neurosarcoidosis, or sarcoidosis affecting the nervous system, a case study shows. The man’s neurosarcoidosis was part of a widespread form of sarcoidosis affecting multiple other organs, including the…
Workplace exposure to silica, mold/mildew, and pesticides were associated with an increased risk of pulmonary sarcoidosis in a recent review study. By analyzing data from dozens of published studies, scientists identified more than 80 different airborne factors that have been linked to the disease in at least one study.
Researchers in Austria and the U.K. have created the first mouse model that mimics the human disease of cardiac sarcoidosis. “To our best knowledge this is the first animal model of cardiac sarcoidosis that recapitulates major … hallmarks of human disease,” scientists wrote, adding that it is expected to…
This year’s Global Virtual Sarcoidosis Summit, hosted by the Foundation for Sarcoidosis Research (FSR), is bringing together the sarcoidosis community under the theme “Find Your Community, Find Your Life.” Those interested in taking part in the summit, happening virtually from Nov. 3 to 5, can register…
The Ann Theodore Foundation and the Milken Institute are once again teaming up to offer grants worth up to $3.4 million to help spur research into sarcoidosis. “Varied perspectives and expertise are key to achieving progress in sarcoidosis research, which will then lead to better treatment,” Lisa…
Higher doses of the investigational therapy efzofitimod significantly reduced relapse rates after a dose of a corticosteroid was reduced in people with pulmonary sarcoidosis, according to a new, pooled analysis of Phase 1b/2a trial data. The first-in-class immunomodulatory therapy, developed by aTyr Pharma, also significantly improved lung…
Treatment with tumor necrosis factor-alpha (TNF-a) inhibitors — which block a type of immune protein in the body — was found to ease signs of inflammation and reduce the need for corticosteroids in people with cardiac sarcoidosis in a new analysis. Safety data, meanwhile, indicated that such treatments were…
Most cardiac sarcoidosis patients respond to six months of first-line treatment with the corticosteroid prednisolone and show reduced active inflammation in the heart, according to a small study in Japan. Cardiovascular events were less common among responders relative to those who respondly poorly, further confirming first-line prednisolone’s effectiveness…
Get regular updates to your inbox.